Nyxoah SA (NASDAQ:NYXH) Receives $11.25 Average Price Target from Analysts

Shares of Nyxoah SA (NASDAQ:NYXH) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $11.25.

A number of research firms recently weighed in on NYXH. Stifel Nicolaus decreased their price objective on Nyxoah from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, March 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 price target on shares of Nyxoah in a research report on Monday, March 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nyxoah in a research report on Monday, December 29th.

Nyxoah Price Performance

Shares of NASDAQ:NYXH opened at $3.17 on Monday. The company has a market cap of $122.87 million, a price-to-earnings ratio of -1.18 and a beta of 1.66. Nyxoah has a one year low of $2.76 and a one year high of $8.64. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.25 and a quick ratio of 1.16. The firm has a 50 day simple moving average of $4.02 and a 200 day simple moving average of $4.69.

Nyxoah (NASDAQ:NYXH) last posted its earnings results on Saturday, February 14th. The company reported ($0.69) earnings per share for the quarter. The business had revenue of $6.62 million for the quarter. Nyxoah had a negative return on equity of 139.18% and a negative net margin of 884.69%. Research analysts predict that Nyxoah will post -1.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nyxoah

Several large investors have recently modified their holdings of NYXH. Heights Capital Management Inc. bought a new stake in shares of Nyxoah during the 4th quarter valued at about $3,575,000. Franklin Resources Inc. grew its stake in Nyxoah by 0.9% during the second quarter. Franklin Resources Inc. now owns 294,990 shares of the company’s stock worth $2,207,000 after purchasing an additional 2,655 shares during the period. Rossmore Private Capital increased its holdings in Nyxoah by 12.6% in the third quarter. Rossmore Private Capital now owns 132,746 shares of the company’s stock worth $616,000 after purchasing an additional 14,806 shares in the last quarter. Kovack Advisors Inc. lifted its stake in Nyxoah by 67.8% in the third quarter. Kovack Advisors Inc. now owns 97,039 shares of the company’s stock valued at $446,000 after buying an additional 39,212 shares during the period. Finally, Shay Capital LLC bought a new position in shares of Nyxoah during the 2nd quarter worth approximately $374,000.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.